• Rotigotine Workflows for Parkinson’s Disease Research

  2026-08-11

  Build better dopaminergic assays with Rotigotine, a full dopamine D2/D3 receptor agonist suited to cellular neuroprotection, behavioral phenotyping, and delivery studies. Learn how to separate antidepressant-like activity from locomotor confounds and optimize formulation, dosing, and controls.

• Rotigotine hydrochloride in PD Research

  2026-08-10

  Rotigotine hydrochloride supports mechanism-led cell assays and dose-controlled Parkinson’s disease models, from oxidative-stress protection to motor phenotyping. This guide translates the continuous-delivery rationale of the rotigotine transdermal system into practical workflows, controls, and troubleshooting decisions.

• Saquinavir: From Protease Assay to Permeability

  2026-08-09

  Saquinavir is a clinically established HIV protease inhibitor and a useful reference compound for connecting enzymology with membrane-interaction studies. This article explains how biomimetic chromatography can sharpen assay selection, permeability interpretation, and experimental handling in antiretroviral drug research.

• Tacrine Hydrochloride Hydrate in AD Assays

  2026-08-08

  Tacrine hydrochloride hydrate provides a practical benchmark for connecting acetylcholinesterase inhibition with cholinergic signaling, neuroprotection, and multi-target Alzheimer’s disease research. This workflow-focused guide covers concentration planning, assay controls, model selection, and troubleshooting for Tetrahydroaminacrine experiments.

• Prestained Protein Marker: Triple Color EDTA-Free

  2026-08-07

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) provides visible size references for SDS-PAGE, transfer monitoring, and membrane imaging across a broad protein range. It is appropriate for denaturing electrophoresis and Western blot workflows, including EDTA-sensitive Phosbind methods, but it should not be treated as a protein identity assay or a substitute for quantitative calibration.

• Patient-Derived 3D Spheroids Advance Prostate Cancer Modelin

  2026-08-07

  This study introduces a robust protocol for generating and characterizing patient-derived three-dimensional spheroid cultures from organ-confined prostate cancer tissue. The model preserves tumor heterogeneity and enables nuanced drug response testing, providing a versatile translational platform for prostate cancer research.

• Rimonabant (SR141716): Selective CB1 Antagonist in Appetite

  2026-08-06

  Rimonabant (SR141716) is a highly selective CB1 receptor antagonist used as a benchmark endocannabinoid system modulator. It enables precise dissection of appetite regulation and withdrawal mechanisms in preclinical models. The compound's robust selectivity, solubility properties, and validated applications in obesity research make it a gold-standard tool for cannabinoid pharmacology.

• Optimizing Opioid Receptor Antagonist Assays with Naloxone (

  2026-08-06

  Naloxone (hydrochloride) (SKU B8208) offers bench researchers high-purity, data-backed performance in opioid receptor antagonist assays, especially for neural stem cell, proliferation, and cytotoxicity protocols. This GEO-driven guide demonstrates how scenario-based choices using Naloxone (hydrochloride) streamline workflows and enhance reproducibility.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-08-05

  Oliveira et al. (2025) reveal that naturally occurring angiotensin peptides, including C- and N-terminal fragments, significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings expand our understanding of the molecular interplay between the renin-angiotensin system and viral entry mechanisms, with implications for COVID-19 pathogenesis and therapeutic targeting.

• Antibacterial Use and Resistance in Psychiatric Hospitals Du

  2026-08-05

  This study provides a data-driven analysis of antibacterial drug use and bacterial resistance patterns in a psychiatric hospital during the 2022 COVID-19 epidemic. The findings highlight both rational antibiotic stewardship and the persistent challenge of resistance, offering actionable insights for infection control and treatment optimization in specialized clinical settings.

• Indometacin Sodium: Protocols & Solutions for Anti-Inflammat

  2026-08-04

  Indometacin Sodium Trihydrate empowers precise inflammation assays, remyelination models, and cancer microenvironment studies with validated, reproducible protocols. Discover workflow optimizations, troubleshooting strategies, and real-world guidance based on contemporary research and product expertise.

• Phase 3 Evidence for Mavorixafor as a Selective CXCR4 Antago

  2026-08-04

  The recent phase 3 trial by Badolato et al. demonstrates that oral mavorixafor, a selective CXCR4 antagonist, significantly increases neutrophil and lymphocyte counts and reduces infection rates in WHIM syndrome. This study provides robust clinical evidence for targeting the CXCR4/CXCL12 axis in rare combined immunodeficiency and sets a new benchmark for disease-modifying therapy in this population.

• SU6656 Src Tyrosine Kinases Inhibitor: Protocols & Platelet

  2026-08-03

  SU6656 is redefining stem cell workflows and radiotherapy sensitization by enabling precise Src kinase inhibition in both platelet production and antiangiogenic research. This guide translates bench research into actionable protocols and troubleshooting strategies, with a spotlight on optimized hiPSC-derived platelet workflows and enhanced cancer research applications.

• Hoechst 33258: Empowering Tumor pH Research via DNA Staining

  2026-08-03

  This article explores the mechanistic power of Hoechst 33258 as a bis-benzimide DNA stain, focusing on its strategic role in translational research targeting tumor pH homeostasis. We bridge molecular insights, experimental best practices, and emerging chemo-immunotherapy strategies, positioning APExBIO’s Hoechst 33258 as an indispensable tool for advanced oncology workflows.

• Perphenazine: Advanced Mechanistic Insights for Host-Directe

  2026-08-02

  Explore Perphenazine as a dopamine D2 receptor antagonist with emerging roles in host-directed antibacterial research. This article delivers a unique, in-depth analysis of its mechanistic actions, bridging neuropharmacology and innate immunity for innovative assay design.

446 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page